Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences Inc (NERV) is a clinical-stage biopharmaceutical company pioneering therapies for central nervous system disorders. This dedicated news hub provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's trajectory in neuroscience innovation.
Discover comprehensive coverage of NERV's press releases including trial results for schizophrenia and Parkinson's disease candidates, partnership announcements with global pharmaceutical leaders, and progress reports on its insomnia/depression therapeutic programs. The page serves as a vital resource for tracking FDA interactions, licensing agreements, and research breakthroughs.
All content is curated to meet investor needs for accurate, up-to-date information while maintaining compliance with financial disclosure standards. Users benefit from consolidated access to essential updates without promotional bias, supported by Minerva's established collaborations with entities like Mitsubishi Tanabe Pharma.
Bookmark this page for streamlined monitoring of NERV's advancements in CNS drug development. Check regularly for new developments impacting the company's position in the competitive biopharma landscape.
Minerva Neurosciences, Inc. (Nasdaq: NERV) reported its Q4 and full-year 2022 financial results and business updates. The company experienced a net loss of $6.7 million in Q4 2022, significantly down from a loss of $21.3 million in Q4 2021. The annual net loss was $32.1 million, compared to $49.9 million in 2021. Research and development expenses decreased to $3.2 million in Q4 from $18.7 million, largely due to a prior year impairment charge. Cash reserves were approximately $36.2 million as of December 31, 2022. The company remains focused on the regulatory path for its lead drug, roluperidone, which faced a Refuse to File letter from the FDA last fall, indicating ongoing dialogue with the agency.
Minerva Neurosciences (Nasdaq: NERV) announced it will release its fiscal year 2022 financial results and business updates on March 8, 2023. A conference call will follow on the same day at 8:30 a.m. Eastern Time. The company focuses on developing therapies for central nervous system disorders. Its product candidates include roluperidone for schizophrenia and MIN-301, currently in pre-clinical development for Parkinson’s disease. Details of the live webcast and subsequent archived session are available on the company’s website.
Minerva Neurosciences (Nasdaq: NERV) announced that the FDA confirmed their refuse to file letter regarding the New Drug Application (NDA) for roluperidone, intended for treating negative symptoms in schizophrenia. This outcome follows a Type A meeting held on November 30, 2022. CEO Dr. Remy Luthringer expressed disappointment but highlighted plans to continue working with the FDA for feedback and assess next steps. Current research indicates a significant patient group suffers from moderate to severe negative symptoms, for which no approved treatments exist in the U.S.
FAQ
What is the current stock price of Minerva Neurosci (NERV)?
What is the market cap of Minerva Neurosci (NERV)?
